SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Exclusion Criteria

• •1. Patients with central nervous system metastasis.
• •2. Patients only have local advanced diseases.
• •3. Patients have uncontrolled pleural, pericardial or abdominal effusion requiring drainage.
• •4. Patients with history of allergy to monoclonal antibodies, any component of SHR-1210, paclitaxel(Albumin Bound) and Gemcitabine.
• •5. Patients have ever received anti PD-1 or anti PD-L1 therapy in the past.
• •6. Patients have accepted any experimental medication.within 4 weeks before the first dose of our experimental medication administration.
• •7. Patients are enrolled in another clinical trial except for observational clinical trial (Non-interventional) or the follow-up of the interventional clinical trial.
• •8. Patients accepted the last dose of anti-cancer therapy (including radiotherapy) within 4 weeks before the first dose of experimental medication administration.
• •9. Patients who need corticosteroid or other immunosuppressive agents.
• •10. Patients who ever received anti-cancer vaccine or have received live vaccine within 4 weeks before the first dose of administration.
• •11. Patients who have received major surgery within 4 weeks before the first dose of administration.
• •12. Patients with active autoimmune diseases, history of autoimmune diseases.
• •13. History of immunodeficiency, including HIV positive test, or other acquired, congenital immunodeficiency disorders, or history of organ transplantation and allogeneic bone marrow transplantation.
• •14. Patients with uncontrolled cardiovascular clinical symptoms or diseases.
• •15. Severe infections occurred within 4 weeks before the first administration.
• •16. History of interstitial lung disease and non- infectious pneumonia.
• •17. Patients with active pulmonary tuberculosis (APTB) infection confirmed by medical history or CT examination.
• •18. Patients with active hepatitis B or hepatitis C.
• •19. Patients with any other malignant tumors diagnosed within 5 years before the first administration.
• •20. Pregnant or lactating women.
• •21. According to the researchers, participants have other factors that may force them to end up the study.